Clinical Trials Logo

Filter by:
NCT ID: NCT01358578 Completed - Clinical trials for Chronic Plaque Psoriasis

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

FIXTURE
Start date: June 2011
Phase: Phase 3
Study type: Interventional

This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.

NCT ID: NCT01358370 Completed - Clinical trials for Lysosomal Acid Lipase Deficiency

A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype

Start date: November 2010
Phase: N/A
Study type: Observational

This is a Natural History study to characterize key aspects of the clinical course of lysosomal acid lipase (LAL) deficiency/Wolman phenotype in patients.

NCT ID: NCT01358266 Completed - Clinical trials for Uveitis; Posterior, Disorder

Study Assessing Double-masked Uveitis Treatment

SAKURA
Start date: May 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution.

NCT ID: NCT01358084 Completed - Clinical trials for Advanced Malignant Pleural Mesothelioma

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM

NGR019
Start date: March 2011
Phase: Phase 2
Study type: Interventional

The main objective of the trial is to document the efficacy of NGR-hTNF administered as maintenance treatment at 0.8 µg/m2 weekly in advanced malignant pleural mesothelioma

NCT ID: NCT01358071 Completed - Ovarian Cancer Clinical Trials

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer

NGR018
Start date: June 2011
Phase: Phase 2
Study type: Interventional

The primary objective of this randomized phase II trial is to compare progression-free survival (PFS) in patients randomized to NGR-hTNF plus an anthracycline versus patients randomized to an anthracycline alone

NCT ID: NCT01357980 Completed - Clinical trials for Detrusor Muscle Hyperactivity

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Start date: May 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of a single dose of 750 U of Dysport compared to placebo for the improvement in the daily incontinence episode frequency for each administration mode in subjects suffering from neurogenic detrusor overactivity following spinal cord injury or multiple sclerosis.

NCT ID: NCT01357265 Completed - Influenza Clinical Trials

Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects

Start date: May 2011
Phase: Phase 2
Study type: Interventional

This study will evaluate safety and immunogenicity of a sub-unit Influenza vaccine when administered to adult and elderly subjects.

NCT ID: NCT01357239 Completed - Fragile X Syndrome Clinical Trials

Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome

Start date: May 2011
Phase: Phase 2
Study type: Interventional

This Phase IIb study is designed to assess whether 3 doses of AFQ056 are safe and effective in treating the behavioral symptoms of Fragile X Syndrome.

NCT ID: NCT01356108 Completed - Clinical trials for Pulmonary Regurgitation

Pulmonic Valve REplacement Multi-discIpline EMEA Registry

PREMIER
Start date: January 2011
Phase:
Study type: Observational

The purpose of this registry is to retrospectively and prospectively obtain clinical data in consecutively treated patients, in order to demonstrate that the commercially available Edwards SAPIEN Valve with the RF3 delivery system is a safe and effective treatment for patients with pulmonary regurgitation or stenosis.

NCT ID: NCT01355627 Completed - Clinical trials for Cerebrospinal Fluid Leaks

TASALL - TachoSil® Against Liquor Leak

Start date: April 2011
Phase: Phase 3
Study type: Interventional

The primary objective is to demonstrate superiority of TachoSil® compared to current practice as an adjunct in sealing the dura mater. The efficacy of the dura mater sealing must be evaluated post-operatively. The secondary objective is to evaluate the safety of TachoSil® as an adjunct in sealing the dura mater. The trial population will consist of 726 randomised (1:1) patients elected for skull base surgery. The trial duration consists of screening, surgery, efficacy follow-up after 7±1 weeks and safety follow-up 28±2 weeks after surgery.